Skip to main content
Clinical Trials/NCT06416956
NCT06416956
Recruiting
Not Applicable

Baby-CINO: CaffeINe Treatment Optimisation in Premature Infants

University of Oxford1 site in 1 country30 target enrollmentStarted: December 11, 2023Last updated:
InterventionsCaffeine

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
30
Locations
1
Primary Endpoint
Brain activity

Overview

Brief Summary

This study investigates how brain activity and breathing changes in premature babies when their dose of caffeine treatment is changed or stopped. The study will assess premature babies receiving caffeine treatment as part of their clinical care. Brain activity will be recorded just before caffeine dose is changed and again two days afterwards. Breathing and other 'vital signs' (breathing rate, heart rate, oxygen saturation) will be recorded from the baby's monitor between the recordings of brain activity and for up to two weeks afterwards.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
— to 37 Weeks (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Born to a mother aged 16 or over
  • Admitted to the Newborn Care Unit, John Radcliffe Hospital
  • Born prematurely (before 37 weeks' gestation)
  • Parent given informed written consent
  • Receiving caffeine citrate

Exclusion Criteria

  • Known chromosomal abnormality or life-threatening congenital abnormality
  • Severe hypoxic insult at birth
  • Intraventricular haemorrhage grade III or IV or other severe neurological pathology

Arms & Interventions

Preterm infant

Preterm infants receiving caffeine (prescribed clinically) will be studied

Intervention: Caffeine (Drug)

Outcomes

Primary Outcomes

Brain activity

Time Frame: From baseline to two days later

Change in EEG activity between baseline (time at which caffeine dose is changed/treatment ends) and approximately 2 days later

Respiration

Time Frame: From baseline to two days later

Change in respiratory dynamics between baseline (time at which caffeine dose is changed/treatment ends) and approximately 2 days later

Secondary Outcomes

  • Heart rate(From baseline to two days later)
  • Oxygen saturation(From baseline to two days later)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials